Koller's insitro snaps up Haystack to build up machine learning tech

Daphne Koller
Daphne Koller, Ph.D. (World Economic Forum/CC BY-SA 2.0)

Machine learning drug development company insitro has bought up Haystack Sciences, adding DNA-encoded libraries (DELs) to its R&D arsenal.

Financial details of the deal with the privately owned Haystack were not made public, but the new buy focuses on synthesizing, breeding and analyzing large combinatorial chemical libraries encoded by DNA sequences known as DELs.

Through the buyout, insitro will tap this DEL technology to collect massive small-molecule data sets that “inform the construction of machine learning models able to predict drug activity from molecular structure,” according to a statement.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

This builds on the company’s recent deal with DiCE Molecules, which also focuses on the DEL field.

RELATED: Insitro nets $143M to ramp up machine learning drug discovery

“We are thrilled to have the Haystack team join insitro,” said Daphne Koller, Ph.D., founder and CEO of the company. “For the past two years, insitro has been building a company focused on the creation of predictive cell-based models of disease in order to enable the discovery of novel targets and evaluate the benefits of new or existing molecules in genetically defined patient segments.

“This acquisition enables us to expand our capabilities to the area of therapeutic design and advances us towards our goal of leveraging machine learning across the entire process of designing and developing better medicines for patients.”

Suggested Articles

GE Healthcare has launched a new algorithm that can read X-rays and help assess the correct placement of ventilator tubes in critical patients.

Months after approving a COVID-19 shot based on early data, Russia is reporting data from nearly 19,000 people showing it is more than 90% effective.

Early-stage biotech Elevian has raised $15 million as it looks to target multiple age-related diseases.